News | January 20, 2009

Invatec Launches First Drug-Eluting Balloon Designed to Treat Atherosclerosis Below the Knee

January 21, 2009 - Invatec this week announced the European launch of a new peripheral balloon, the IN.PACT Amphirion paclitaxel-eluting PTA balloon catheter.

This is the first drug-eluting catheter designed specifically to treat atherosclerosis in arteries located below the knee (BtK). IN.PACT features FreePac, a proprietary coating that frees and separates paclitaxel molecules and facilitates their absorption into the wall of the artery. The FreePac coating was developed in close collaboration with the researchers who pioneered drug-eluting balloon therapy, Ulrich Speck, Ph.D., department of radiology at Charite Mitte, Berlin and Bruno Scheller, M.D., University Hospital, department of internal medicine, Homburg/Saar.

The company said drug-eluting balloons utilizing a special drug elution formulation have demonstrated effectiveness in the treatment of atherosclerosis and the prevention of restenosis.

Invatec plans to launch a randomized trial, the IN.PACT DEEP study, in the first half of 2009, to provide additional data about the effectiveness of this new treatment concept.

“After years of research we are pleased to see this technology available for clinical applications,” commented Prof. Speck and Prof. Scheller. “The drug-eluting balloon concept has the potential to reduce re-intervention rates for patients with atherosclerosis. Invatec’s balloon technology is an ideal platform for the FreePac coating and will allow for the development of specific solutions for additional endovascular applications including the superficial femoral artery (SFA).”

Prof. Dierk Scheinert, course director of the LINC interventional course in Leipzig, commented on the first IN.PACT Amphirion procedure, “Combining conventional balloon dilatation with local drug administration is a fascinating new concept for this patient group. Stents may not be a feasible option for the majority of BtK patients with advanced disease. The IN.PACT Amphirion therefore holds promise as an effective treatment for this challenging patient population.”

Impaired blood flow caused by blockages below the knee, also known as critical limb ischemia (CLI) result in pain, poor wound healing, gangrene and a high risk of death. According to data published in Wounds, 40 percent of patients require amputation within 12 months of a CLI episode, and there is an annual mortality rate of more than 20 percent.

For more information: www.invatec.com

Related Content

News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter
News | Chronic Total Occlusion (CTO)| June 28, 2017
June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Sponsored Content | Videos | EP Lab| May 17, 2017
This video, provided by Spectranetics, demonstrates how to deploy the Bridge Occlusion Balloon used to seal accidenta
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Artery Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons| April 26, 2017
Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Balloon Catheter at...
Overlay Init